{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:51:39Z","timestamp":1784224299505,"version":"3.55.0"},"reference-count":262,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmmc-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular and Cellular Cardiology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.yjmcc.2026.04.007","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T15:14:45Z","timestamp":1776957285000},"page":"52-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pathophysiology and pharmacotherapy of cardiovascular complications in metabolic syndrome"],"prefix":"10.1016","volume":"215","author":[{"given":"Naranjan S.","family":"Dhalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chigar A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh V.","family":"Beladiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita A.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejal R.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yjmcc.2026.04.007_bb0005","author":"World Health Organization (WHO). Cardiovascular diseases (CVDs) 2021 [cited"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0010","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1093\/eurheartj\/ehac245","article-title":"Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke","volume":"43","author":"Lip","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0015","first-page":"330","article-title":"The evolving global burden of cardiovascular diseases: what lies ahead. Eur","author":"Tsampasian","year":"2024","journal-title":"J Prev Cardiol"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0020","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/ije\/dyv337","article-title":"Cohort Profile: The Framingham Heart Study (FHS): overview of milestones in cardiovascular epidemiology","volume":"44","author":"Tsao","year":"2015","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0025","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2105\/AJPH.2003.026419","article-title":"Becoming the Framingham Study 1947-1950","volume":"95","author":"Oppenheimer","year":"2005","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0030","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jjcc.2013.11.006","article-title":"Adipokines: A link between obesity and cardiovascular disease","volume":"63","author":"Nakamura","year":"2014","journal-title":"J. Cardiol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0035","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jacc.2013.05.016","article-title":"High-Sensitivity C-Reactive Protein and Cardiovascular Disease: A Resolute Belief or an Elusive Link?","volume":"62","author":"Yousuf","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0040","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1046\/j.1538-7836.2003.00279.x","article-title":"Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk","volume":"1","author":"Juhan-Vague","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0045","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1530\/JOE-16-0211","article-title":"Adipose tissue in control of metabolism","volume":"231","author":"Luo","year":"2016","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0050","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0055","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12933-018-0762-4","article-title":"Association between insulin resistance and the development of cardiovascular disease","volume":"17","author":"Ormazabal","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0060","first-page":"59","article-title":"Prevalence and Risk Factors of Metabolic Syndrome: A Prospective Study on Cardiovascular Health","author":"Rus","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0065","first-page":"18","article-title":"Metabolic Syndrome and Coronary Artery Disease Risk: A Meta-Analysis of Observational Studies","author":"Alshammary","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0070","series-title":"Biochem Mech Metab Syndr","first-page":"3","article-title":"The Biochemical Symphony of Metabolic Syndrome: An Intricate Introduction","author":"Gandhi","year":"2024"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0075","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1741-7015-9-48","article-title":"Metabolic syndrome: definitions and controversies","volume":"9","author":"Kassi","year":"2011","journal-title":"BMC Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0080","doi-asserted-by":"crossref","DOI":"10.1177\/03000605231164548","article-title":"Insulin resistance and cardiovascular disease","volume":"51","author":"Kosmas","year":"2023","journal-title":"J Int Med Res"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jseint.2023.08.019","article-title":"Components of metabolic syndrome as significant risk factors for postoperative complications following total shoulder arthroplasty: hypertension, diabetes, and obesity","volume":"8","author":"Fassler","year":"2024","journal-title":"JSES Int"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.trsl.2020.08.007","article-title":"TMAO: how gut microbiota contributes to heart failure","volume":"228","author":"Zhang","year":"2021","journal-title":"Transl. Res."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0095","doi-asserted-by":"crossref","first-page":"1469393","DOI":"10.3389\/fbioe.2024.1469393","article-title":"Reactive oxygen species (ROS)-responsive biomaterials for treating myocardial ischemia-reperfusion injury","volume":"12","author":"Zhang","year":"2024","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0100","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-022-01055-2","article-title":"Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials","volume":"7","author":"Shi","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0105","first-page":"10","article-title":"SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain","author":"Rolek","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0110","doi-asserted-by":"crossref","first-page":"1368835","DOI":"10.3389\/fphar.2024.1368835","article-title":"NLRP3 inflammasome and pyroptosis in cardiovascular diseases and exercise intervention","volume":"15","author":"Ding","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0115","doi-asserted-by":"crossref","first-page":"1074911","DOI":"10.3389\/fendo.2022.1074911","article-title":"PPAR\u03b1: An emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0120","first-page":"10","article-title":"The Endocannabinoid System and PPARs: Focus on Their Signalling Crosstalk, Action and Transcriptional Regulation","author":"Iannotti","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109924","article-title":"Geographic distribution of metabolic syndrome and its components in the general adult population: A meta-analysis of global data from 28 million individuals","volume":"188","author":"Noubiap","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0130","first-page":"11","article-title":"Metabolic Syndrome and Chronic Disease Risk in South Asian Immigrants: A Review of Prevalence, Factors, and Interventions","author":"Mahadevan","year":"2023","journal-title":"Healthc (Basel, Switzerland)"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0135","series-title":"Biochem Mech Metab Syndr","first-page":"527","article-title":"Future Directions and Emerging Research in Metabolic Syndrome","author":"Patel","year":"2024"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0140","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/07853890500401234","article-title":"The metabolic syndrome and cardiovascular disease","volume":"38","author":"Bonora","year":"2006","journal-title":"Ann. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0145","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jacc.2010.05.034","article-title":"The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis","volume":"56","author":"Mottillo","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0150","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1161\/01.CIR.0000140762.04598.F9","article-title":"National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study","volume":"110","author":"Hunt","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0155","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/archinte.164.10.1066","article-title":"Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women","volume":"164","author":"Hu","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0160","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1464-5491.2003.01068.x","article-title":"The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study","volume":"21","author":"Bonora","year":"2004","journal-title":"Diabet. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0165","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/01.CIR.0000055014.62083.05","article-title":"C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women","volume":"107","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0170","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1161\/01.CIR.0000080897.52664.94","article-title":"Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study","volume":"108","author":"Sattar","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0175","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2337\/diacare.26.4.1251","article-title":"Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study","volume":"26","author":"Bonora","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0180","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1001\/jama.288.21.2709","article-title":"The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men","volume":"288","author":"Lakka","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0185","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2337\/diacare.24.4.683","article-title":"Cardiovascular morbidity and mortality associated with the metabolic syndrome","volume":"24","author":"Isomaa","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0190","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.amjmed.2006.02.031","article-title":"Metabolic syndrome and risk of cardiovascular disease: a meta-analysis","volume":"119","author":"Galassi","year":"2006","journal-title":"Am. J. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0195","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12933-022-01665-8","article-title":"Gender differences in changes in metabolic syndrome status and its components and risk of cardiovascular disease: a longitudinal cohort study","volume":"21","author":"Ramezankhani","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0200","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12933-020-01166-6","article-title":"Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort","volume":"19","author":"Guembe","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0205","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3390\/diabetology4020015","article-title":"Progress in Understanding Metabolic Syndrome and Knowledge of Its Complex Pathophysiology","volume":"4","author":"Jha","year":"2023","journal-title":"Diabetology"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0210","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s41043-023-00415-0","article-title":"Prevalence of metabolic syndrome and components in rural, semi-urban and urban areas in the littoral region in Cameroon: impact of physical activity","volume":"42","author":"Bilog","year":"2023","journal-title":"J. Health Popul. Nutr."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0215","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2147\/DMSO.S336384","article-title":"Development and Validation of a Simple Risk Model for Predicting Metabolic Syndrome (MetS) in Midlife: A Cohort Study","volume":"15","author":"Ibrahim","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0220","article-title":"Insulin Resistance and Coronary Artery Disease: Untangling the Web of Endocrine-Cardiac Connections","volume":"15","author":"Ashraf","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0225","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/joneph\/20.1.10","article-title":"Insulin resistance, metabolic syndrome and endothelial dysfunction","volume":"20","author":"Bigazzi","year":"2007","journal-title":"J Nephrol"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0230","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1586\/17446651.2014.878646","article-title":"Insulin resistance: a key therapeutic target for cardiovascular risk reduction in obese patients?","volume":"9","author":"Karki","year":"2014","journal-title":"Expert. Rev. Endocrinol. Metab."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0235","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1161\/CIRCULATIONAHA.105.563213","article-title":"Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms","volume":"113","author":"Kim","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0240","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/dmrr.634","article-title":"Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases","volume":"22","author":"Cersosimo","year":"2006","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0245","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1172\/JCI200314172","article-title":"Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension","volume":"111","author":"Landmesser","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0250","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s11897-012-0097-5","article-title":"Recoupling the cardiac nitric oxide synthases: tetrahydrobiopterin synthesis and recycling","volume":"9","author":"Alkaitis","year":"2012","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0260","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.redox.2017.06.001","article-title":"Nox2 contributes to hyperinsulinemia-induced redox imbalance and impaired vascular function","volume":"13","author":"Mahmoud","year":"2017","journal-title":"Redox Biol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20153775","article-title":"Endothelial Dysfunction: Is There a Hyperglycemia-Induced Imbalance of NOX and NOS?","volume":"20","author":"Meza","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0270","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1172\/JCI29069","article-title":"Inflammation and insulin resistance","volume":"116","author":"Shoelson","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0275","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/jir.2008.0027","article-title":"Monocyte chemoattractant protein-1 (MCP-1): an overview","volume":"29","author":"Deshmane","year":"2009","journal-title":"J Interf cytokine Res Off J Int Soc Interf Cytokine Res"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0280","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11154-012-9229-1","article-title":"Role of insulin resistance in endothelial dysfunction","volume":"14","author":"Muniyappa","year":"2013","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0285","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1089\/ars.2010.3522","article-title":"Vascular cell adhesion molecule-1 expression and signaling during disease: regulation by reactive oxygen species and antioxidants","volume":"15","author":"Cook-Mills","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0290","series-title":"New Transcr Factors their Role Diabetes its Ther","first-page":"279","article-title":"Insulin resistance, inflammation, and the IKK\/I\u03baB\/NF-\u03baB pathway","author":"Bhatt","year":"2006"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0295","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2478\/jtim-2022-0012","article-title":"Inflammatory Factors Driving Atherosclerotic Plaque Progression New Insights","volume":"10","author":"Song","year":"2022","journal-title":"J Transl Intern Med"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0300","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ddstr.2008.02.001","article-title":"Oxidative mechanisms and atherothrombotic cardiovascular disease","volume":"5","author":"Leopold","year":"2008","journal-title":"Drug Discov Today Ther Strateg"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112906","article-title":"The Role of Inflammation in Cardiovascular Disease","volume":"23","author":"Henein","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0310","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S0008-6363(03)00516-9","article-title":"Matrix metalloproteinases: A review of their structure and role in acute coronary syndrome","volume":"59","author":"Jones","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0315","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0320","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s11010-022-04587-x","article-title":"Impairment of insulin signaling pathway PI3K\/Akt\/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective review","volume":"478","author":"Ramasubbu","year":"2023","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0325","article-title":"Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications","volume":"8","author":"Gallo","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0330","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jacc.2011.11.082","article-title":"Endothelial Dysfunction, Arterial Stiffness, and Heart Failure","volume":"60","author":"Marti","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0335","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.amjmed.2007.01.003","article-title":"Effect of Insulin Resistance, Dyslipidemia, and Intra-abdominal Adiposity on the Development of Cardiovascular Disease and Diabetes Mellitus","volume":"120","author":"Rader","year":"2007","journal-title":"Am. J. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.117545","article-title":"Modification of lipoprotein metabolism and function driving atherogenesis in diabetes","volume":"394","author":"Luciani","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0345","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00005-012-0210-1","article-title":"Inflammation, cytokines and insulin resistance: a clinical perspective","volume":"61","author":"Wieser","year":"2013","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21239042","article-title":"Visceral Obesity and Its Shared Role in Cancer and Cardiovascular Disease: A Scoping Review of the Pathophysiology and Pharmacological Treatments","volume":"21","author":"Aparecida Silveira","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0355","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s10020-024-01019-y","article-title":"The interplay of factors in metabolic syndrome: understanding its roots and complexity","volume":"30","author":"Islam","year":"2024","journal-title":"Mol. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0360","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12982-025-00496-8","article-title":"Interconnected epidemics: obesity, metabolic syndrome, diabetes and cardiovascular diseases\u2014insights from research and prevention strategies","volume":"22","author":"Gupta","year":"2025","journal-title":"Discov Public Heal"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20092358","article-title":"Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications","volume":"20","author":"Longo","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0370","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314982","article-title":"The Role of Adipokines in Inflammatory Mechanisms of Obesity","volume":"23","author":"Kirichenko","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0375","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41574-024-01047-y","article-title":"Inflammation and resolution in obesity","volume":"21","author":"Sot\u00e1k","year":"2025","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0380","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/s41598-025-85519-9","article-title":"Severe obesity, high inflammation, insulin resistance with risks of all-cause mortality and all-site cancers, and potential modification by healthy lifestyles","volume":"15","author":"Jin","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0385","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.biopha.2017.10.122","article-title":"Nitric oxide bioavailability dysfunction involves in atherosclerosis","volume":"97","author":"Chen","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0390","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3346\/jkms.2015.30.9.1213","article-title":"Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches","volume":"30","author":"Park","year":"2015","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0395","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.CIR.0000060923.07573.F2","article-title":"Obesity, Insulin Resistance, Diabetes, and Cardiovascular Risk in Children","volume":"107","author":"Steinberger","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103264","article-title":"Hyperinsulinemia and insulin resistance in the obese may develop as part of a homeostatic response to elevated free fatty acids: A mechanistic case-control and a population-based cohort study","volume":"65","author":"Fryk","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0405","doi-asserted-by":"crossref","unstructured":"Zhang Y, Zhang Z, Tu C, Chen X, He R. Advanced Glycation End Products in Disease Development and Potential Interventions. Antioxidants 2025;14. https:\/\/www.mdpi.com\/2076-3921\/14\/4\/492.","DOI":"10.3390\/antiox14040492"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0410","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2337\/dsi23-0013","article-title":"Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care","volume":"37","author":"Nogueira","year":"2024","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0415","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.tem.2011.04.007","article-title":"Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance","volume":"22","author":"Choi","year":"2011","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0420","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.2337\/diabetes.48.9.1787","article-title":"Sympathetic activation of leptin via the ventromedial hypothalamus: leptin-induced increase in catecholamine secretion","volume":"48","author":"Satoh","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0425","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1081\/CEH-200031948","article-title":"Loss of leptin actions in obesity: two concepts with cardiovascular implications","volume":"26","author":"Mark","year":"2004","journal-title":"Clin. Exp. Hypertens."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0430","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3389\/fendo.2020.00354","article-title":"Role of Leptin in Cardiovascular Diseases","volume":"11","author":"Poetsch","year":"2020","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0435","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1161\/CIRCRESAHA.107.156596","article-title":"Leptin Signaling and Obesity","volume":"101","author":"Yang","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0440","doi-asserted-by":"crossref","first-page":"6184","DOI":"10.3390\/ijms15046184","article-title":"Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease","volume":"15","author":"Jung","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0445","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1210\/er.2005-0005","article-title":"Adiponectin and Adiponectin Receptors","volume":"26","author":"Kadowaki","year":"2005","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0450","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1476-5381.2011.01395.x","article-title":"Adiponectin and cardiovascular health: an update","volume":"165","author":"Hui","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0455","doi-asserted-by":"crossref","first-page":"1490143","DOI":"10.3389\/fendo.2024.1490143","article-title":"Multifaced roles of adipokines in endothelial cell function","volume":"15","author":"Yan","year":"2024","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0460","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/MOH.0b013e3283634443","article-title":"Mechanisms of thrombosis in obesity","volume":"20","author":"Blokhin","year":"2013","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0465","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1182\/blood-2013-05-427708","article-title":"Inflammation, obesity, and thrombosis","volume":"122","author":"Samad","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0470","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/BF03344054","article-title":"Coagulation and fibrinolysis abnormalities in obesity","volume":"25","author":"De Pergola","year":"2002","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0475","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1016\/j.jacl.2024.01.006","article-title":"Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: Consensus statement IV","volume":"18","author":"Puri","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0480","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.amjcard.2016.04.004","article-title":"Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease","volume":"118","author":"Budoff","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2021.06.398","article-title":"Creation and evaluation of predictive equations for the indirect small-dense LDL level calculation from basics lipid parameters of lipid profile","volume":"331","author":"Velilla","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0490","doi-asserted-by":"crossref","first-page":"1409653","DOI":"10.3389\/fendo.2024.1409653","article-title":"Triglyceride-rich lipoproteins and cardiovascular diseases","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0495","doi-asserted-by":"crossref","unstructured":"Vekic J, Stromsnes K, Mazzalai S, Zeljkovic A, Rizzo M, Gambini J. Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk. Biomedicines 2023;11. https:\/\/www.mdpi.com\/2227-9059\/11\/11\/2897.","DOI":"10.3390\/biomedicines11112897"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0500","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.2337\/db11-0425","article-title":"Fatty acids, obesity, and insulin resistance: time for a reevaluation","volume":"60","author":"Karpe","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0505","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MOL.0000000000000067","article-title":"The composition and metabolism of large and small LDL","volume":"25","author":"Diffenderfer","year":"2014","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0510","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1242\/jcs.182097","article-title":"Oxidized LDL induces FAK-dependent RSK signaling to drive NF-\u03baB activation and VCAM-1 expression","volume":"129","author":"Yurdagul","year":"2016","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0515","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/714653","article-title":"The role of oxidized low-density lipoproteins in atherosclerosis: the myths and the facts","volume":"2013","author":"Maiolino","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0520","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1074\/jbc.270.1.319","article-title":"Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase","volume":"270","author":"Liao","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0525","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11883-004-0099-1","article-title":"Matrix metalloproteinases and atherosclerosis","volume":"6","author":"Watanabe","year":"2004","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0530","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0021-9150(99)00479-7","article-title":"The role of plaque rupture and thrombosis in coronary artery disease","volume":"149","author":"Zaman","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0535","first-page":"14","article-title":"Dysfunctional High-Density Lipoprotein Cholesterol and Coronary Artery Disease: A","author":"Madaudo","year":"2024","journal-title":"Narrative Review. J Pers Med"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0540","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/MED.0000000000000136","article-title":"Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease","volume":"22","author":"Kohan","year":"2015","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0545","article-title":"Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis","volume":"9","author":"Zhang","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0550","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.925923","article-title":"Mechanisms of Oxidized LDL-Mediated Endothelial Dysfunction and Its Consequences for the Development of Atherosclerosis","volume":"9","author":"Jiang","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0555","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41392-022-01125-5","article-title":"Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics","volume":"7","author":"Duan","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0560","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s11906-012-0245-z","article-title":"The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome","volume":"14","author":"Thethi","year":"2012","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0565","first-page":"26","article-title":"Direct Vascular Effects of Angiotensin II (A Systematic Short Review)","author":"N\u00e1dasy","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0570","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","article-title":"Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology","volume":"98","author":"Forrester","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0575","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1089\/ars.2012.4604","article-title":"Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease","volume":"19","author":"Dikalov","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0580","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1089\/ars.2012.4641","article-title":"Angiotensin II, NADPH oxidase, and redox signaling in the vasculature","volume":"19","author":"Nguyen Dinh Cat","year":"2013","journal-title":"Antioxid. Redox Signal."},{"issue":"68","key":"10.1016\/j.yjmcc.2026.04.007_bb0585","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1161\/HYPERTENSIONAHA.116.07792","article-title":"Central Angiotensin-II Increases Blood Pressure and Sympathetic Outflow via Rho Kinase Activation in Conscious Rabbits","volume":"Tex 1979","author":"Pellegrino","year":"2016","journal-title":"Hypertens Dallas"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0590","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1007\/s00018-010-0460-1","article-title":"RhoA\/Rho-kinase and vascular diseases: what is the link?","volume":"67","author":"Nunes","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0595","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/hr.2011.173","article-title":"Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications","volume":"35","author":"Kalil","year":"2012","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0600","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153357","article-title":"\u03b23-Adrenergic receptor downregulation leads to adipocyte catecholamine resistance in obesity","volume":"132","author":"Valentine","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0605","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.652152","article-title":"Current Developments on the Role of \u03b1(1)-Adrenergic Receptors in Cognition, Cardioprotection, and Metabolism","volume":"9","author":"Perez","year":"2021","journal-title":"Front cell Dev Biol"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0610","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2147\/vhrm.2006.2.2.145","article-title":"Metabolic syndrome, inflammation and atherosclerosis","volume":"2","author":"Paoletti","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0615","doi-asserted-by":"crossref","first-page":"114","DOI":"10.37349\/ec.2024.00026","article-title":"Laboratory markers of metabolic syndrome","volume":"2","author":"Morgado","year":"2024","journal-title":"Explor Cardiol"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0620","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25189802","article-title":"Hypoxia in Human Obesity: New Insights from Inflammation towards Insulin Resistance-A Narrative Review","volume":"25","author":"Mirabelli","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0625","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1038\/sj.ijo.0802501","article-title":"Inflammation and the IKK\u03b2\/I\u03baB\/NF-\u03baB axis in obesity- and diet-induced insulin resistance","volume":"27","author":"Shoelson","year":"2003","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0630","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0635","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1042\/CS20080196","article-title":"Role of TNF-alpha in vascular dysfunction","volume":"116","author":"Zhang","year":"2009","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0640","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1089\/ars.2008.2220","article-title":"NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology","volume":"11","author":"Frey","year":"2009","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0645","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00395-008-0733-0","article-title":"The role of inflammatory cytokines in endothelial dysfunction","volume":"103","author":"Zhang","year":"2008","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0650","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12933-023-01965-7","article-title":"The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction","volume":"22","author":"An","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2023.117487","article-title":"ICAM-1 and VCAM-1: Gatekeepers in various inflammatory and cardiovascular disorders","volume":"548","author":"Singh","year":"2023","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0660","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/cvr\/cvad130","article-title":"Targeting endothelial vascular cell adhesion molecule-1 in atherosclerosis: drug discovery and development of vascular cell adhesion molecule-1-directed novel therapeutics","volume":"119","author":"Pickett","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0665","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1007\/s00125-012-2644-8","article-title":"Regulation of insulin sensitivity by serine\/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2","volume":"55","author":"Copps","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0670","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1161\/01.ATV.0000015078.09208.92","article-title":"Role of Nuclear Factor-\u03baB Activation in Metalloproteinase-1, -3, and -9 Secretion by Human Macrophages In Vitro and Rabbit Foam Cells Produced In Vivo","volume":"22","author":"Chase","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0675","doi-asserted-by":"crossref","first-page":"1257988","DOI":"10.3389\/fimmu.2023.1257988","article-title":"Research progress of NF-\u03baB signaling pathway and thrombosis","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0680","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.it.2011.05.004","article-title":"NLRP3 inflammasomes link inflammation and metabolic disease","volume":"32","author":"De Nardo","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0685","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011765","article-title":"Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation","volume":"5","author":"Rajam\u00e4ki","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0690","doi-asserted-by":"crossref","first-page":"29402","DOI":"10.1074\/jbc.M115.680199","article-title":"Macrophage-specific de Novo Synthesis of Ceramide Is Dispensable for Inflammasome-driven Inflammation and Insulin Resistance in Obesity","volume":"290","author":"Camell","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0695","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-22-0184","article-title":"NLRP3 inflammasome activation, metabolic danger signals, and protein binding partners","volume":"257","author":"Leu","year":"2023","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0700","first-page":"23","article-title":"The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches","author":"Tsioufis","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0705","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fcvm.2018.00062","article-title":"Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond","volume":"5","author":"Aday","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0710","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41598-024-85041-4","article-title":"The effect of NLRP3 inflammasome on cardiovascular prognosis in patients with acute coronary syndrome","volume":"15","author":"Mo","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0715","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.molimm.2022.04.003","article-title":"IL-6 regulates induction of C-reactive protein gene expression by activating STAT3 isoforms","volume":"146","author":"Ngwa","year":"2022","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0720","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1161\/01.ATV.0000029781.31325.66","article-title":"Interrelationships Among Circulating Interleukin-6, C-Reactive Protein, and Traditional Cardiovascular Risk Factors in Women","volume":"22","author":"Bermudez","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0725","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/jama.286.3.327","article-title":"C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus","volume":"286","author":"Pradhan","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0730","doi-asserted-by":"crossref","first-page":"297","DOI":"10.31083\/j.rcm2410297","article-title":"C-Reactive Protein in Atherosclerosis-More than a Biomarker, but not Just a Culprit","volume":"24","author":"Kirkg\u00f6z","year":"2023","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0735","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MOL.0b013e32832ac03e","article-title":"Human C-reactive protein and the metabolic syndrome","volume":"20","author":"Devaraj","year":"2009","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0740","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1161\/01.ATV.0000242905.41404.68","article-title":"PAI-1 and the Metabolic Syndrome","volume":"26","author":"Alessi","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0745","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1161\/STROKEAHA.111.622217","article-title":"Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases","volume":"43","author":"Tj\u00e4rnlund-Wolf","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0750","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1161\/ATVBAHA.121.317380","article-title":"A Thromboxane A(2) Receptor-Driven COX-2-Dependent Feedback Loop That Affects Endothelial Homeostasis and Angiogenesis","volume":"42","author":"Eckenstaler","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0755","doi-asserted-by":"crossref","first-page":"1221438","DOI":"10.3389\/fnut.2023.1221438","article-title":"Endothelial dysfunction, platelet hyperactivity, hypertension, and the metabolic syndrome: molecular insights and combating strategies","volume":"10","author":"Das","year":"2023","journal-title":"Front Nutr"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0760","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.coph.2004.10.003","article-title":"Hypercoagulability in the metabolic syndrome","volume":"5","author":"Nieuwdorp","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0765","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.pharma.2024.08.005","article-title":"Cardiovascular disease and thrombosis: Intersections with the immune system, inflammation, and the coagulation system","volume":"83","author":"Rajput","year":"2025","journal-title":"Ann. Pharm. Fr."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0770","first-page":"11","article-title":"Pathophysiology of Coagulation and Emerging Roles for Extracellular Vesicles in Coagulation Cascades and Disorders","author":"Al-Koussa","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0775","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.thromres.2017.05.009","article-title":"Platelet hyperactivation, apoptosis and hypercoagulability in patients with acute pulmonary embolism","volume":"155","author":"Rezania","year":"2017","journal-title":"Thromb. Res."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0780","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/ajcn\/nqac074","article-title":"Gut microbiota-derived metabolite trimethylamine-N-oxide and multiple health outcomes: an umbrella review and updated meta-analysis","volume":"116","author":"Li","year":"2022","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0785","first-page":"17","article-title":"Dietary Fatty Acids Modulate Gut Microbiota-Derived Trimethylamine-N-Oxide: Potential Mechanisms and Future Perspective","author":"Kilic","year":"2025","journal-title":"Nutrients"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0790","doi-asserted-by":"crossref","DOI":"10.3390\/ph16040504","article-title":"Gut-Derived Metabolite, Trimethylamine-N-oxide (TMAO) in Cardio-Metabolic Diseases: Detection, Mechanism, and Potential Therapeutics","volume":"16","author":"Shanmugham","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0795","doi-asserted-by":"crossref","first-page":"936","DOI":"10.17305\/bb.2023.8893","article-title":"The roles of trimethylamine-N-oxide in atherosclerosis and its potential therapeutic aspect: A literature review","volume":"23","author":"Oktaviono","year":"2023","journal-title":"Biomol Biomed"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0800","doi-asserted-by":"crossref","first-page":"6498","DOI":"10.1038\/ncomms7498","article-title":"Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis","volume":"6","author":"Miao","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0805","doi-asserted-by":"crossref","first-page":"8873","DOI":"10.1038\/s41467-025-63905-1","article-title":"Adipocyte FMO3-derived TMAO induces WAT dysfunction and metabolic disorders by promoting inflammasome activation in ageing","volume":"16","author":"Ganapathy","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0810","first-page":"27","article-title":"Epigenetic regulation and molecular mechanisms in cardiovascular diseases: a review of recent advances and therapeutic implications","author":"M\u0142ynarska","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0815","series-title":"Nanotheranostics Metab Syndr Transform Diagnosis Ther","first-page":"33","article-title":"Pathophysiology Mechanism in Therapeutics of Metabolic Syndrome","author":"Singh","year":"2026"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0820","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCRESAHA.115.305206","article-title":"The Role of DNA Methylation in Cardiovascular Risk and Disease: Methodological Aspects, Study Design, and Data Analysis for Epidemiological Studies","volume":"118","author":"Zhong","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0825","series-title":"Nanotheranostics Metab Syndr Transform Diagnosis Ther","first-page":"33","article-title":"Pathophysiology mechanism in therapeutics of metabolic syndrome","author":"Singh","year":"2026"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0830","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1161\/ATVBAHA.115.305046","article-title":"Histone Deacetylases and Cardiometabolic Diseases","volume":"35","author":"Yiew","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0835","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3892\/etm.2025.12882","article-title":"Role and research progress of histone modification in cardiovascular diseases (Review)","volume":"30","author":"Qi","year":"2025","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0840","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MED.0b013e32833727a1","article-title":"MicroRNAs in atherosclerosis and lipoprotein metabolism","volume":"17","author":"Vickers","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0845","first-page":"23","article-title":"miRNA in Ischemic Heart Disease and Its Potential as Biomarkers: A Comprehensive Review","author":"Kong","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0255","doi-asserted-by":"crossref","first-page":"11632","DOI":"10.1021\/acs.jmedchem.3c00770","article-title":"NADPH Oxidases: From Molecular Mechanisms to Current Inhibitors","volume":"66","author":"Cipriano","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0855","first-page":"13","article-title":"Adipose Tissue Insulin Resistance: A Key Driver of Metabolic Syndrome Pathogenesis","author":"Rabiee","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0860","doi-asserted-by":"crossref","first-page":"547","DOI":"10.17305\/bb.2025.13145","article-title":"Mitochondrial dysfunction, reactive oxygen species, and diabetes mellitus - A triangular relationship: A review","volume":"26","author":"Manojlovic","year":"2025","journal-title":"Biomol Biomed"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0865","doi-asserted-by":"crossref","first-page":"463","DOI":"10.5114\/aoms.2015.52350","article-title":"Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns","volume":"11","author":"Papaetis","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0870","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s43162-024-00342-4","article-title":"Gut microbiota-derived metabolites: implications for metabolic syndrome and therapeutic interventions","volume":"36","author":"Olalekan","year":"2024","journal-title":"Egypt J Intern Med"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0875","first-page":"14","article-title":"Mitochondrial Dysfunction in the Development and Progression of Cardiometabolic Diseases: A Narrative Review","author":"Pliouta","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0880","doi-asserted-by":"crossref","first-page":"30569","DOI":"10.1021\/acs.jafc.5c08378","article-title":"Gut Microbiota-Derived Metabolites and Cardiovascular Disease: Focus on Trimethylamine-N-oxide","volume":"73","author":"He","year":"2025","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0885","first-page":"207","article-title":"Role of epigenetics in cardiovascular diseases: An out and out check","volume":"1","author":"Wasim","year":"2023","journal-title":"Intell Pharm"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0890","series-title":"Pharmacological Interventions of Metabolic Syndrome BT - Biochemical Mechanisms for Metabolic Syndrome","first-page":"433","author":"Mehta","year":"2024"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0895","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.diabres.2003.10.001","article-title":"Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle-aged Japanese men","volume":"64","author":"Nakanishi","year":"2004","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0900","first-page":"243","article-title":"A \u201c20\/20\u201d Match: ACC\/AHA 2017 versus ESC\/ESH 2018 Guidelines for Management of Hypertension","volume":"30","author":"Pradhan","year":"2021","journal-title":"Int J Angiol Off Publ Int Coll Angiol Inc"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0905","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0910","first-page":"114","article-title":"Blood pressure control and cardiovascular risk reduction","volume":"11","author":"Antonakoudis","year":"2007","journal-title":"Hippokratia"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0915","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3317\/jraas.2000.002","article-title":"The HOPE Study (Heart Outcomes Prevention Evaluation)","author":"Sleight","year":"2000","journal-title":"J Renin Angiotensin Aldosterone Syst England"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0920","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0925","first-page":"7","article-title":"Influence of the angiotensin system on endothelial and smooth muscle cell migration","volume":"137","author":"Bell","year":"1990","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0930","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1748-1716.1961.tb02267.x","article-title":"The comparative effects of angiotensin and noradrenaline on consecutive vascular sections","volume":"53","author":"Folkow","year":"1961","journal-title":"Acta Physiol. Scand."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0935","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jacc.2005.05.051","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"46","author":"Abuissa","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0940","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2337\/dc10-2224","article-title":"Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial","volume":"34","author":"van der Zijl","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0945","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1001121","article-title":"Effect of valsartan on the incidence of diabetes and cardiovascular events","volume":"362","author":"McMurray","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0950","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12967-020-02314-y","article-title":"Real-world use of ACEI\/ARB in diabetic hypertensive patients before the initial diagnosis of obstructive coronary artery disease: patient characteristics and long-term follow-up outcome","volume":"18","author":"Zhang","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0955","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1524-6175.2002.01099.x","article-title":"The Losartan Intervention for Endpoint Reduction (LIFE) trial-have angiotensin-receptor blockers come of age?","volume":"4","author":"Sica","year":"2002","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0960","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ahj.2008.05.017","article-title":"Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial","volume":"156","author":"Califf","year":"2008","journal-title":"Am. Heart J."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0965","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pharmtox-010818-021214","article-title":"The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson\u2019s Disease","volume":"59","author":"Liss","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0970","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1097\/CCM.0000000000003654","article-title":"Effect of Antihypertensive Medications on Sepsis-Related Outcomes: A Population-Based Cohort Study","volume":"47","author":"Kim","year":"2019","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0975","series-title":"Calcium Channel Blocker Toxicity","author":"Chakraborty","year":"2025"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0980","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1007\/s00268-019-04935-x","article-title":"Bradycardia During Laparoscopic Surgeries: A Retrospective Cohort Study","volume":"43","author":"Dabush-Elisha","year":"2019","journal-title":"World J. Surg."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0985","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1524-6175.2003.02259.x","article-title":"Results of the ALLHAT trial: is the debate about initial antihypertensive drug therapy over?","author":"Moser","year":"2003","journal-title":"J. Clin. Hypertens. (Greenwich). United States"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb0990","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.2165\/00003495-200767090-00005","article-title":"Dihydropyridine calcium channel antagonists in the management of hypertension","volume":"67","author":"Epstein","year":"2007","journal-title":"Drugs"},{"issue":"55","key":"10.1016\/j.yjmcc.2026.04.007_bb0995","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1161\/HYPERTENSIONAHA.109.148999","article-title":"Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study","volume":"Tex 1979","author":"Boutouyrie","year":"2010","journal-title":"Hypertens Dallas"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1000","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF03256573","article-title":"Metabolic effects of manidipine","volume":"9","author":"Cavalieri","year":"2009","journal-title":"Am J Cardiovasc drugs drugs, devices, other Interv"},{"issue":"19","key":"10.1016\/j.yjmcc.2026.04.007_bb1005","first-page":"I119","article-title":"Obesity hypertension. Converting enzyme inhibitors and calcium antagonists","volume":"Tex 1979","author":"Frohlich","year":"1992","journal-title":"Hypertens Dallas"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1010","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/BF00054207","article-title":"Lack of effect of nicardipine and diltiazem on glucose- and arginine-induced insulin release in obese subjects","volume":"2","author":"Pezzarossa","year":"1988","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1015","doi-asserted-by":"crossref","first-page":"318S","DOI":"10.1093\/ajh\/3.10.318","article-title":"Nifedipine gastrointestinal therapeutic system in the treatment of hypertension. Results of a multicenter trial. The Modern Approach to the Treatment of Hypertension (MATH) Study Group","volume":"3","author":"Krakoff","year":"1990","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1025","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1751-7176.2009.00169.x","article-title":"Prevention of heart failure with chlorthalidone in ALLHAT: placing the results into perspective","author":"Massie","year":"2009","journal-title":"J. Clin. Hypertens. (Greenwich). United States"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1030","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1161\/CIRCULATIONAHA.105.544031","article-title":"Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","volume":"113","author":"Davis","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1035","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/MNH.0b013e328305b9a5","article-title":"Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia","volume":"17","author":"Reungjui","year":"2008","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1040","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2125.1999.00092.x","article-title":"The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes","volume":"48","author":"King","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1045","doi-asserted-by":"crossref","DOI":"10.1016\/S1262-3636(03)72788-8","article-title":"Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes","volume":"29","author":"Despr\u00e9s","year":"2003","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1050","doi-asserted-by":"crossref","first-page":"27707","DOI":"10.1038\/s41598-025-13211-z","article-title":"Effects of metformin treatment on the risk of acute myocardial infarction","volume":"15","author":"Chang","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2025.101100","article-title":"Cardiovascular outcomes of metformin use in non-diabetic patients with hypertension and hyperlipidemia: a retrospective cohort study","volume":"23","author":"Kamel","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1060","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1161\/CIRCULATIONAHA.118.034516","article-title":"Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke","volume":"138","author":"Verma","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1065","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1070","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/dom.14760","article-title":"Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial","volume":"24","author":"Franek","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1080","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1085","first-page":"2247","article-title":"Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome","volume":"373","author":"Brian","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1090","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1095","first-page":"644","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Bruce","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5334\/gh.1258","article-title":"Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis","volume":"18","author":"Ali","year":"2023","journal-title":"Glob. Heart"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1105","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Richard","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1110","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/dom.14385","article-title":"Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy","volume":"23","author":"Lingvay","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1120","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.atherosclerosis.2008.08.022","article-title":"The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis","volume":"203","author":"Blum","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1125","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic Effects of Statins on the Cardiovascular System","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1130","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/MOL.0b013e328341a5a8","article-title":"Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective","volume":"22","author":"Elam","year":"2011","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/clp.10.84","article-title":"The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus","volume":"6","author":"Elam","year":"2011","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1140","first-page":"55","article-title":"Ezetimibe in the Treatment of Patients with Metabolic Diseases","volume":"9","author":"Nehme","year":"2013","journal-title":"Eur Endocrinol"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1145","first-page":"247","article-title":"Ezetimibe: Clinical and Scientific Meaning of the IMPROVE-IT Study","volume":"106","author":"Correia","year":"2016","journal-title":"Arq. Bras. Cardiol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1150","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100997","article-title":"Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis","volume":"38","author":"Khan","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1155","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/0976-500X.195906","article-title":"Proprotein convertase subtilisin\/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia","volume":"7","author":"Mazhar","year":"2016","journal-title":"J. Pharmacol. Pharmacother."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1160","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/1573403X13666170918165713","article-title":"Effects of Evolocumab on Cardiovascular Events","volume":"13","author":"Mikhail","year":"2017","journal-title":"Curr. Cardiol. Rev."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1165","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/CIRCULATIONAHA.119.043826","article-title":"Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES","volume":"140","author":"Jukema","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1170","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S2213-8587(23)00316-9","article-title":"Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial","volume":"12","author":"Ray","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1175","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1180","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1185","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1093\/cvr\/cvab350","article-title":"Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?","volume":"118","author":"Nurmohamed","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1190","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11883-024-01231-5","article-title":"Obicetrapib-the Rebirth of CETP Inhibitors?","volume":"26","author":"Chang","year":"2024","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1195","first-page":"15","article-title":"Inclisiran-Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9","author":"Wo\u0142owiec","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1200","doi-asserted-by":"crossref","first-page":"375","DOI":"10.31083\/j.rcm2311375","article-title":"Inclisiran: A New Pharmacological Approach for Hypercholesterolemia","volume":"23","author":"Di Fusco","year":"2022","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1205","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0300-483X(82)90060-9","article-title":"Inhibition of hepatic lipogenesis by salicylate","volume":"24","author":"Beynen","year":"1982","journal-title":"Toxicology"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1210","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/00365517809108413","article-title":"Mechanisms for inhibition of free fatty acid mobilization by nicotinic acid and sodium salicylate in canine subcutaneous adipose tissue in situ","volume":"38","author":"Vik-Mo","year":"1978","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1215","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.tem.2013.06.002","article-title":"AMPK: mediating the metabolic effects of salicylate-based drugs?","volume":"24","author":"Steinberg","year":"2013","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1220","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1126\/science.1215327","article-title":"The ancient drug salicylate directly activates AMP-activated protein kinase","volume":"336","author":"Hawley","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1225","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1159\/000430162","article-title":"Enhanced Glucose Tolerance and Pancreatic Beta Cell Function by Low Dose Aspirin in Hyperglycemic Insulin-Resistant Type 2 Diabetic Goto-Kakizaki (GK) Rats","volume":"36","author":"Amiri","year":"2015","journal-title":"Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1230","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041391","article-title":"P2Y(12) Inhibition beyond Thrombosis: Effects on Inflammation","volume":"21","author":"Mansour","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1235","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2125.2011.03949.x","article-title":"Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?","volume":"72","author":"Ma","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1240","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.thromres.2024.02.010","article-title":"The effects of CYP2C19 genotype polymorphism and clopidogrel resistance on ischemic event occurrence in patients with peripheral arterial disease undergoing revascularization: A prospective cohort study","volume":"236","author":"Zhang","year":"2024","journal-title":"Thromb. Res."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1245","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/jpm8010008","article-title":"Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine","author":"Brown","year":"2018","journal-title":"J Pers Med"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1250","doi-asserted-by":"crossref","first-page":"e1876","DOI":"10.1097\/MJT.0000000000000237","article-title":"Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes","volume":"23","author":"Husted","year":"2016","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1255","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2023.107143","article-title":"Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease","volume":"148","author":"Jain","year":"2023","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1260","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11239-011-0667-5","article-title":"P2Y12 platelet inhibition in clinical practice","volume":"33","author":"Damman","year":"2012","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1265","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1270","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1111\/dom.13702","article-title":"Effects of colchicine in adults with metabolic syndrome: A pilot randomized controlled trial","volume":"21","author":"Demidowich","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1275","first-page":"14","article-title":"The Action of Colchicine in Patients with Metabolic Syndrome and Obesity: Perspectives and Challenges","author":"Bulh\u00f5es","year":"2024","journal-title":"Metabolites"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115542","article-title":"Discovery of a novel 1,3,4-oxadiazol-2-one-based NLRP3 inhibitor as a pharmacological agent to mitigate cardiac and metabolic complications in an experimental model of diet-induced metaflammation","volume":"257","author":"Gastaldi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1285","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2147\/DMSO.S299570","article-title":"Hepatic Knockdown of Endothelin Type A Receptor (ETAR) Ameliorates Hepatic Insulin Resistance and Hyperglycemia Through Suppressing p66Shc-Mediated Mitochondrial Fragmentation in High-Fat Diet-Fed Mice","volume":"14","author":"Feng","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1290","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1124\/jpet.114.215566","article-title":"Combined Endothelin A Blockade and Chlorthalidone Treatment in a Rat Model of Metabolic Syndrome","volume":"351","author":"Jin","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1295","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1300","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1305","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1310","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1136\/gutjnl-2020-323071","article-title":"Gut microbiota-derived metabolites as central regulators in metabolic disorders","volume":"70","author":"Agus","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.yjmcc.2026.04.007_bb1315","first-page":"1","article-title":"Precision medicine and metabolic syndrome","volume":"18","author":"Gharipour","year":"2022","journal-title":"ARYA Atheroscler"}],"container-title":["Journal of Molecular and Cellular Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282826000581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282826000581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:36:50Z","timestamp":1783021010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022282826000581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":262,"alternative-id":["S0022282826000581"],"URL":"https:\/\/doi.org\/10.1016\/j.yjmcc.2026.04.007","relation":{},"ISSN":["0022-2828"],"issn-type":[{"value":"0022-2828","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathophysiology and pharmacotherapy of cardiovascular complications in metabolic syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular and Cellular Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yjmcc.2026.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}